Digestive System TRIZ Cases

Combining BAR502 with a statin or UDCA reduces hepatic lipid deposition, insulin resistance, and liver damage in NAFLD and NASH.

A trigger-released esophageal film keeps anti-inflammatory drug at the mucosal site longer, improving local efficacy while limiting side effects.

Indeglitazar treats MASH and other fibrotic liver diseases by reducing inflammation and fibrosis while avoiding major side effects of corticosteroids.

High β-glucan and α-fucan extracts replace in-feed antibiotics by improving gut flora balance, reducing harmful bacteria, and supporting animal performance.

Cyclophilin-inhibiting cyclosporine analogues such as CRV431 help prevent, delay, and reverse fibrosis across multiple organs.

Neutralizing PSMP helps block chemotactic signaling that drives liver, lung, and kidney fibrosis when treatment options are limited.

Beta-glucan thickening helps dysphagia nutrition stay cohesive under shear, reducing aspiration risk without raising swallowing effort.

Lytic bacteriophages target adherent-invasive E. coli in IBD, offering a route beyond ineffective antibiotics and symptom-only care.

Engineered anti-TSLP antibodies improve affinity and isoform specificity while blocking TSLP-TSLPR/IL7R signaling for Th2-related disease treatment.

Irsogladine reduces eosinophil infiltration across the GI tract, helping induce remission and lower relapse in eosinophilic gastrointestinal disease.

Herbal extracts such as PHY906 and Scutellaria baicalensis reduce checkpoint inhibitor GI side effects while preserving anti-tumor activity.

Controlled-release microparticles target the intervertebral disc to extend pain relief, lower infection risk, and avoid invasive surgery.

Amino acid carbonate prodrugs improve pterostilbene solubility and stability, enabling liver-protective NAFLD and NASH treatment.

Targeted capsid amino acid substitutions add galactose binding to AAV2, expanding cell entry pathways and boosting transgene expression.

A capsicum, bentonite, and yeast cell wall feed composition helps calves grow better while reducing scours and supporting gut health.

Standardized herbal extracts in feed or water help prevent cryptosporidiosis while improving gut integrity, immunity, and inflammation control.

A mixed urea, biuret, and nitrate supplement improves rumen nitrogen use while lowering methane and ammonia toxicity risk.

Machine-learning analysis of polymorphism combinations predicts which IBD patients are likely to respond to anti-TL1A antibodies.

Controlled hydration and gelation form an odor-free konjac food solid without alkaline treatment, improving satiety and blood glucose stability.

Anti-ceramide antibodies neutralize ceramide-mediated apoptosis to protect intestinal stem cells and mitigate ARS mortality and GvHD.

These FXR agonists target intestinal FXR to increase FGF19 secretion and reduce bile acid synthesis while limiting systemic agonism.

Function-blocking antibodies target the α11β1–type I collagen interaction to inhibit myofibroblast differentiation and reduce fibrosis.